CoChat

Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors

Open access
Smith, Steven G., Sanchez, Roberto, Zhou, Ming-Ming · 2014 · Chemistry & Biology
Cited by 81

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Chemical compounds built on a diazepine scaffold have recently emerged as potent inhibitors of the acetyl-lysine binding activity of bromodomain-containing proteins, which is required for gene transcriptional activation in cancer and inflammation. Not only have these chemical compounds validated bromodomains as attractive epigenetic drug targets, but they have also brought to the forefront another application of the diazepine, which had already been regarded as a versatile chemical scaffold in rational drug design. This article reviews the success of diazepine compounds as therapeutic agents and examines the unique chemical and geometric features of this privileged scaffold that make it an excellent template for developing potent and selective molecules that control bromodomain-related gene expression in human diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2014.03.004

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Selective inhibition of BET bromodomains

    Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 6×

    “For example, one of the main structural features of JQ1 is a bulky t-butyl ester group attached at C3 (Figure 4C), which is cited as the reason that JQ1 shows little activity against the BZD allosteric binding site on the GABAA receptor (Filippakopoulos et al., 2010).”
    BackgroundMethodInfluential
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×

    “…BRD4, have recently been shown to play an important role in the pathways that cause multiple types of cancer, including acute myeloid leukemia (Zuber et al., 2011), mixed lineage leukemia (Dawson et al., 2011), multiple myeloma (Mertz et al., 2011), and an aggressive form of squamous…”
    Background
  • Structure and ligand of a histone acetyltransferase bromodomain

    Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732 · cited 2×

    “First reported as the acetyl-lysine binding domain in the transcriptional co-activator PCAF in 1999 (Dhalluin et al., 1999), the bromodomain functions to bind acetylated lysines in histones and nonhistone proteins, thereby controlling acetylation-mediated protein-protein interactions in gene…”
    BackgroundSelf-citation
  • Suppression of inflammation by a synthetic histone mimic

    Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563

  • Privileged scaffolds for library design and drug discovery

    Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509 · cited 1×

    “…that is important to agonist binding—receptor isoforms rely on many different residues to interact with different functional groups on BZD ligands (Amin et al., 1997; Buhr et al., 1996, 1997; Kucken et al., 2000; Pritchett and Seeburg, 1991; Richter et al., 2012; Wieland and Lüddens, 1994).”
    Background
  • Epigenetic protein families: a new frontier for drug discovery

    Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327 · cited 1×

    “Inhibitors of bromodomain-containing proteins are a part of the extensive pipeline of epigenetic modulators that has the potential to bring advanced, targeted treatments to patients in the near future (Arrowsmith et al., 2012; Dawson et al., 2012; DeWoskin and Million, 2013; Kelly et al., 2010).”
    Background
  • Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

    Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172

  • Molecular and neuronal substrate for the selective attenuation of anxiety

    Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 1×

    “…and through the use of BZD inhibition in the altered mice and in wild-type mice, were able to determine the activities controlled by each a subtype (Crestani et al., 2001, 2002; Löw et al., 2000; McKernan et al., 2000; van Rijnsoever et al., 2004; Rudolph et al., 1999; Rudolph and Knoflach, 2011).”
    Method
  • Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype

    McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944

  • Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes

    Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733 · cited 1×

    “…and through the use of BZD inhibition in the altered mice and in wild-type mice, were able to determine the activities controlled by each a subtype (Crestani et al., 2001, 2002; Löw et al., 2000; McKernan et al., 2000; van Rijnsoever et al., 2004; Rudolph et al., 1999; Rudolph and Knoflach, 2011).”
    Method

Show all 13 references

Cited by

Metadata

Authors
Smith, S. G., Sanchez, R., & Zhou, M.-M.
Venue
Chemistry & Biology
Publisher
Elsevier BV
Published
2014-05
Volume
21
Issue
5
Pages
573-583
ISSN
1074-5521 (ISSN-L)
OpenAlex
W2085538883
Cited by
81
References
13
FWCI
3.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.